POLARGO: Randomized Phase III Study of Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

被引：1
|
作者：
Matasar, Matthew J. [1 ]
Haioun, Corinne [2 ]
Sancho, Juan-Manuel [3 ]
Viardot, Andreas [4 ]
Hirata, Jamie [5 ]
Perretti, Thomas [6 ]
Musick, Lisa [5 ]
McMillan, Andrew K. [7 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Groupe Hosp Henri Mondor, Lymphoid Malignancies Unit, Creteil, France
[3] ICO HU Germans Trias Pujol, Barcelona, Spain
[4] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany
[5] Genentech Inc, South San Francisco, CA USA
[6] F Hoffmann Roche Ltd, Basel, Switzerland
[7] Nottingham Univ Hosp NHS Trust, Ctr Clin Haematol, Nottingham, England
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-145857
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3568
引用
收藏
页数：5
相关论文
共 50 条
  • [31] SUNMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin vs rituximab plus gemcitabine and oxaliplatin in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
    Westin, Jason
    Olszewski, Adam J.
    Fogliatto, Laura
    Kim, Won Seog
    Shin, Ho-Jin
    Jeon, Young-Woo
    Norasetthada, Lalita
    Pavlovsky, Astrid
    Rego, Eduardo
    Wu, Hao
    Yin, Shen
    Batlevi, Connie Lee
    Pham, Song
    Penuel, Elicia M.
    Jing, Jing
    Wei, Michael C.
    Budde, Lihua Elizabeth
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] Polatuzumab vedotin plus bendamustine and rituximab (Pola-BR) was effective for neurolymphomatosis in a patient with refractory diffuse large B-cell lymphoma
    Shinmura, Kohei
    Okubo, So
    Kadota, Saori
    Nakayama, Hitomi
    Sakurai, Aki
    Kurosawa, Shuhei
    Ito, Chisako
    Aisa, Yoshinobu
    Nakazato, Tomonori
    [J]. ANNALS OF HEMATOLOGY, 2023, 102 (01) : 223 - 225
  • [33] Updated results of a phase Ib/II randomised study: polatuzumab vedotin (Pola) plus bendamustine (B) and rituximab (R) in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
    Sehn, L. H.
    McMillan, A.
    Matasar, M. J.
    Flowers, C. R.
    Kamdar, M.
    Hertzberg, M.
    Assouline, S.
    Kim, T. M.
    Kim, W. S.
    Ozcan, M.
    Croft, B.
    Herrera, A. F.
    Hirata, J.
    Cheng, J.
    Ku, G.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 93 - 94
  • [34] Polatuzumab vedotin plus bendamustine and rituximab (Pola-BR) was effective for neurolymphomatosis in a patient with refractory diffuse large B-cell lymphoma
    Kohei Shinmura
    So Okubo
    Saori Kadota
    Hitomi Nakayama
    Aki Sakurai
    Shuhei Kurosawa
    Chisako Ito
    Yoshinobu Aisa
    Tomonori Nakazato
    [J]. Annals of Hematology, 2023, 102 : 223 - 225
  • [35] Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey
    Dal, Mehmet Sinan
    Ulu, Bahar Uncu
    Uzay, Ant
    Akay, Olga Meltem
    Besisik, Sevgi
    Yenerel, Mustafa Nuri
    Celik, Serhat
    Kaynar, Leylagul
    Yucel, Orhan Kemal
    Deveci, Burak
    Sonmez, Mehmet
    Mehtap, Ozgur
    Bekoz, Huseyin Saffet
    Sunu, Cenk
    Salim, Ozan
    Ulas, Turgay
    Karti, Sami
    Altuntas, Fevzi
    Ferhanoglu, Burhan
    Tuglular, Tulin Firat
    [J]. ANNALS OF HEMATOLOGY, 2023, 102 (01) : 133 - 140
  • [36] Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey
    Mehmet Sinan Dal
    Bahar Uncu Ulu
    Ant Uzay
    Olga Meltem Akay
    Sevgi Beşışık
    Mustafa Nuri Yenerel
    Serhat Çelik
    Leylagül Kaynar
    Orhan Kemal Yücel
    Burak Deveci
    Mehmet Sönmez
    Özgür Mehtap
    Hüseyin Saffet Beköz
    Cenk Sunu
    Ozan Salim
    Turgay Ulaş
    Sami Kartı
    Fevzi Altuntaş
    Burhan Ferhanoğlu
    Tülin Fırat Tuğlular
    [J]. Annals of Hematology, 2023, 102 : 133 - 140
  • [37] Cost-Effectiveness of Polatuzumab Vedotin Plus Bendamustine-Rituximab for Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the United States
    Betts, Keith A.
    Felizzi, Federico
    Dieye, Ibou
    Li, Jia
    Schulz, Mathias
    Hong, Samuel J.
    Masaquel, Anthony S.
    [J]. BLOOD, 2020, 136
  • [38] Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study
    Sehn, Laurie H.
    Hertzberg, Mark
    Opat, Stephen
    Herrera, Alex F.
    Assouline, Sarit
    Flowers, Christopher R.
    Kim, Tae Min
    McMillan, Andrew K.
    Ozcan, Muhit
    Safar, Violaine
    Salles, Gilles
    Hirata, Jamie
    Yang, Annie
    Musick, Lisa
    Matasar, Matthew J.
    [J]. BLOOD, 2022, 140 : 9464 - 9467
  • [39] Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Ohmachi, Ken
    Niitsu, Nozomi
    Uchida, Toshiki
    Kim, Seok Jin
    Ando, Kiyoshi
    Takahashi, Naoki
    Takahashi, Naoto
    Uike, Naokuni
    Eom, Hyeon Seok
    Chae, Yee Soo
    Terauchi, Takashi
    Tateishi, Ukihide
    Tatsumi, Mitsuaki
    Kim, Won Seog
    Tobinai, Kensei
    Suh, Cheolwon
    Ogura, Michinori
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (17) : 2103 - +
  • [40] Effective treatment with polatuzumab vedotin of relapsed and refractory primary cutaneous diffuse large B-cell lymphoma leg type
    Satoko Oka
    Kazuo Ono
    Masaharu Nohgawa
    [J]. Annals of Hematology, 2022, 101 : 2353 - 2354
12345